Trials / Completed
CompletedNCT01944800
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 4,018 (actual)
- Sponsor
- Deutsches Herzzentrum Muenchen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ticagrelor | Loading dose of 180 mg, followed by maintenance dose of 180 mg per day |
| DRUG | Prasugrel | Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/\> 75 years or \< 60 kg |
Timeline
- Start date
- 2013-09-15
- Primary completion
- 2019-07-01
- Completion
- 2021-09-01
- First posted
- 2013-09-18
- Last updated
- 2023-02-06
Locations
19 sites across 2 countries: Germany, Italy
Source: ClinicalTrials.gov record NCT01944800. Inclusion in this directory is not an endorsement.